Heather Eckenrode
Family · Martinsburg, WVNPI 1881971588
Payments from drug & device makers
Across 97 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$459
- GSK$165
- AstraZeneca$161
- Amgen$142
- Lilly USA, LLC$141
- Pfizer$137
- plus $638 from 16 others
What the payments were for
- Food & beverage$1,844100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $459 |
| GSK | 9 | $165 |
| AstraZeneca | 9 | $161 |
| Amgen | 8 | $142 |
| Lilly USA, LLC | 9 | $141 |
| Pfizer | 8 | $137 |
| Merck | 6 | $112 |
| Gilead | 4 | $89 |
| Novo Nordisk | 4 | $78 |
| Viiv Healthcare Company | 3 | $74 |
| Bayer | 2 | $46 |
| Seqirus USA Inc | 2 | $36 |
| Exact Sciences | 1 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Abbott | 2 | $30 |
| Organogenesis Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$1,844 in reported general payments places this provider in the 75th percentile of 1,507 family providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 21 | $79,893 |
| MounjaroTirzepatide | 35 | $43,452 |
| TrulicityDulaglutide | 30 | $38,209 |
| OzempicSemaglutide | 26 | $23,705 |
| EliquisApixaban | 21 | $13,464 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $11,149 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $6,700 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,094 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,642 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,998 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 69 | $1,602 |
| Atorvastatin Calcium | 181 | $1,553 |
| Potassium Chloride | 15 | $1,474 |
| Pantoprazole Sodium | 64 | $881 |
| Omeprazole | 49 | $816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $141 | $81,66165 claims |
| GileadBiktarvy | $89 | $79,89321 claims |
| Novo NordiskOzempic | $78 | $23,70526 claims |
| PfizerEliquis | $137 | $13,46421 claims |
| GSKIncruse Ellipta, Arnuity Ellipta | $165 | $9,34230 claims |
| AstraZenecaSymbicort | $161 | $3,09412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,507 family providers in West Virginia.
Other family in Martinsburg
- Stephanie GladdenMartinsburg$7K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.